The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
- Cat.No. Product Name Information
- C3080 AD57 (hydrochloride) polypharmacological cancer therapeutic that inhibits RET.
- A4237 Amuvatinib (MP-470, HPK 56) Tyrosine kinase inhibitor
- A4116 Danusertib (PHA-739358) Pan-aurora kinase inhibitor
- A8236 Regorafenib Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
- A3750 Regorafenib hydrochloride Tyrosine kinase inhibitor
- A3751 Regorafenib monohydrate Tyrosine kinase inhibitor
- C4239 RPI-1 ATP-dependent RET kinase inhibitor
- A3847 SU5416 VEGF receptor inhibitor and AHR agonist
- A4145 TG101209 JAK2/3 inhibitor